Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aimmune Therap (NQ: AIMT )

34.49 USD UNCHANGED
Last Price Updated: 7:11 PM EDT, Oct 12, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Aimmune Therap

< Previous 1 2 3 4 5 6 7 Next >
New Research Coverage Highlights Avery Dennison, Raymond James Financial, Genuine Parts, Kimco Realty, Bristow Group, and Aimmune Therapeutics — Consolidated Revenues, Company Growth, and Expectations
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Avery Dennison Corporation... 
From GlobeNewswire News Releases
Aimmune Therapeutics Appoints Dr. Jayson Dallas as CEO
Aimmune Therapeutics appoints Dr. Jayson Dallas as CEO, effective June 19, 2018. 
From Business Wire News Releases
Aimmune Therapeutics Announces New Pan-European Study Showing Significant Psychosocial Burden Associated With Peanut Allergy
Aimmune Therapeutics announces new pan-European study shows significant psychosocial burden of peanut allergy for children, parents, and adults. 
From Business Wire News Releases
Aimmune Therapeutics Announces Data on Terminology Used with Oral Immunotherapy Were Presented at EAACI 2018
Aimmune Therapeutics presented data at EAACI on oral immunotherapy terminology showing allergists want consensus and prefer the term "tolerated" dose. 
From Business Wire News Releases
Aimmune Therapeutics Announces New Clinical Data on AR101 for Peanut Allergy at the 2018 EAACI Congress
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, reported additional results from its pivotal Phase 3... 
From Business Wire News Releases
Aimmune Therapeutics to Present Data on Peanut Allergy at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018
Aimmune Therapeutics will will present data on peanut allergy at EAACI 2018 in Munich May 26-30. 
From Business Wire News Releases
Aimmune Therapeutics to Participate in Four Upcoming Investor Conferences in May and June
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team... 
From Business Wire News Releases
Aimmune Therapeutics Announces First Quarter 2018 Financial Results
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the first quarter 2018. As of... 
From Business Wire News Releases
Market Trends Toward New Normal in Genuine Parts, Energizer, Arthur J. Gallagher, Aimmune Therapeutics, Roku, and Premier — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Genuine Parts Company... 
From GlobeNewswire News Releases
Technical Perspectives on Biotech Stocks -- Aimmune Therapeutics, Atara Biotherapeutics, AveXis, and Axsome Therapeutics
From PR Newswire
Aimmune Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results
Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the fourth quarter and full year... 
From Business Wire News Releases
Aimmune Therapeutics to Participate in Four Investor Conferences in March
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team... 
From Business Wire News Releases
Aimmune Therapeutics Presents Results From the Positive, Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy at AAAAI-WAO
Aimmune Therapeutics presents results from the positive, pivotal Phase 3 PALISADE trial of AR101 for peanut allergy at AAAAI-WAO. 
From Business Wire News Releases
Aimmune Therapeutics Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock
Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the underwriters of its previously... 
From Business Wire News Releases
Aimmune Therapeutics to Host Analyst and Investor Event Following Oral Late-Breaking Presentation of Phase 3 PALISADE Results on Sunday, March 4, at the AAAAI-WAO Joint Congress in Orlando
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host an Analyst and Investor Event on the... 
From Business Wire News Releases
Aimmune Therapeutics Announces Closing of Public Offering of Common Stock
Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the completion of its previously announced... 
From Business Wire News Releases
Aimmune Therapeutics Announces Pricing of Public Offering of Common Stock
Aimmune Therapeutics announces pricing of public offering of common stock. 
From Business Wire News Releases
Aimmune Therapeutics Announces Proposed Public Offering of Common Stock
Aimmune Therapeutics announces proposed offering of common stock. 
From Business Wire News Releases
Aimmune Therapeutics’ Pivotal Phase 3 PALISADE Trial of AR101 Meets Primary Endpoint in Patients With Peanut Allergy
Aimmune Therapeutics announced that its pivotal Phase 3 PALISADE efficacy trial of AR101 met the primary endpoint. 
From Business Wire News Releases
Aimmune Therapeutics Expands Scientific Advisory Board With Appointments of George du Toit, M.B., B.Ch., and Wayne Shreffler, M.D., Ph.D.
Aimmune Therapeutics expands Scientific Advisory Board with appointments of George du Toit, M.B., B.Ch., and Wayne Shreffler, M.D., Ph.D. 
From Business Wire News Releases
Aimmune Therapeutics Announces Presentations at 2018 AAAAI-WAO Joint Congress
Aimmune to present at AAAAI. 
From Business Wire News Releases
Report: Exploring Fundamental Drivers Behind Stericycle, Hemisphere Media Group, Expedia, Olin, Aimmune Therapeutics, and Waste Management — New Horizons, Emerging Trends, and Upcoming Developments
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Stericycle, Inc.... 
From GlobeNewswire News Releases
Aimmune Therapeutics Broadens and Extends Supply Agreement With Golden Peanut and Tree Nuts for AR101 for Peanut Allergy
Aimmune Therapeutics broadens and extends supply agreement with Golden Peanut and Tree Nuts for AR101 for peanut allergy. 
From Business Wire News Releases
Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data from Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy
Aimmune announces 2018 outlook, including upcoming topline data in February from pivotal Phase 3 PALISADE trial of AR101 for peanut allergy. 
From Business Wire News Releases
Aimmune Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that CEO Stephen Dilly, M.B.B.S., Ph.D., will present a... 
From Business Wire News Releases
Aimmune Therapeutics to Participate in the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on December 14
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that Chief Financial Officer Eric Bjerkholt will... 
From Business Wire News Releases
Aimmune Therapeutics to Host Investor Symposium on Peanut Allergy Treatment with Leading Expert Allergists on Friday, December 1
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host an Investor Symposium in New York... 
From Business Wire News Releases
Report: Developing Opportunities within UGI, Party City Holdco, Old Dominion Freight Line, Olin, Aimmune Therapeutics, and Waste Management — Future Expectations, Projections Moving into 2018
In new a independent research report released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of UGI Corporation... 
From GlobeNewswire News Releases
Aimmune Therapeutics Announces Third Quarter 2017 Financial Results and Planned Retirement of CEO by the End of 2018
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter and nine months ended... 
From Business Wire News Releases
Aimmune Therapeutics to Participate in Four Investor Conferences in November
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team... 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
X